OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion, Eli Lilly Australia Pty Ltd, CON-1171
Product name
OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion
Sponsor name
Eli Lilly Australia Pty Ltd
Consent start
Consent no.
CON-1171
Duration
The consent is effective from 26 September 2023 until 30 September 2026.
Standard
Paragraphs 8(1)(f) & 10(4)(h) & Paragraphs 8(1)(g) & 10(4)(i) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
- The batch number of the medicine is not preceded by a batch number prefix on the label. The batch number prefix is instead located on the label either below the batch number or above the batch number combined with the expiry date prefix.
- The expiry date of the medicine, is not preceded by an expiry date prefix on the label. The expiry date prefix is instead located on the label either below the expiry date or above the expiry date combined with the batch number prefix.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Prescription medicines